A Phase 3 interventional study of somatropin in Growth Hormone Disorder, Growth Hormone Deficiency in Children and Growth Disorder, sponsored by Novo Nordisk A/S. Completed at 40 sites in United States. Open to participants aged 3 Years to 15 Years. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
This trial is conducted in the United States of America (USA). The purpose of the trial is to compare the effect of Norditropin® using different dosing regimens in children suspected of growth hormone deficiency.
164 studies on the registry are indexed under Dwarfism, Pituitary; 25 are open to participants now.
This study's enrollment of 173 is above the median of 72 across 122 interventional studies indexed under Dwarfism, Pituitary.
Browse Dwarfism, Pituitary studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Change in height standard deviation score
Time frame: 24 month
IGF-I
IGFBP-3
free IGF-I
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S